Study endpoints
toxicity, tumor
INFLAMMATION, TUMOR
The primary endpoint is PFS. Secondary endpoints are OS, overall response rate (ORR), quality of life (QoL), toxicity and rate of hospitalizations during treatment. Exploratory endpoints include evaluation of pretreatment characteristics and geriatric screening tools as predictive markers, and correlation between plasma biomarkers of systemic inflammation, circulating tumor DNA (ctDNA), tissue biomarkers of resistance to chemotherapy, and outcome.